Evotec Historical Cash Flow
| EVO Stock | USD 4.18 0.18 4.13% |
Analysis of Evotec SE cash flow over time is an excellent tool to project Evotec SE ADR future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Depreciation of 97.6 M or Other Non Cash Items of 16.3 M as it is a great indicator of Evotec SE ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Evotec SE ADR latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Evotec SE ADR is a good buy for the upcoming year.
Evotec |
About Evotec Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Evotec balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Evotec's non-liquid assets can be easily converted into cash.
Evotec SE Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Most accounts from Evotec SE's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Evotec SE ADR current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evotec SE ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. At this time, Evotec SE's Other Cashflows From Investing Activities is very stable compared to the past year.
Evotec SE cash flow statement Correlations
Click cells to compare fundamentals
Evotec SE Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Evotec SE cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 145.5M | 276.7M | (284.2M) | 95.8M | 110.1M | 115.6M | |
| Free Cash Flow | (54.4M) | 3.3M | 21.8M | (182.0M) | (179.6M) | (170.6M) | |
| Change In Working Capital | (36.9M) | (2.3M) | 119.3M | (9.9M) | (11.4M) | (10.9M) | |
| Begin Period Cash Flow | 277.0M | 422.6M | 699.3M | 415.2M | 477.4M | 501.3M | |
| Other Cashflows From Financing Activities | 1.6M | (20.7M) | (5.7M) | (12.6M) | (12.9M) | (12.2M) | |
| Depreciation | 56.1M | 67.6M | 81.7M | 99.9M | 93.0M | 97.6M | |
| Other Non Cash Items | 6.5M | (171.5M) | 160.2M | 232.3M | 24.4M | 16.3M | |
| Capital Expenditures | 99.1M | 118.9M | 181.4M | 216.0M | 248.4M | 260.8M | |
| Total Cash From Operating Activities | 44.7M | 122.2M | 203.1M | 34.0M | 36.4M | 31.0M | |
| Net Income | 6.3M | 215.5M | (175.7M) | (83.9M) | (96.5M) | (91.7M) | |
| Total Cash From Financing Activities | 246.4M | 398.4M | (52.4M) | 84.8M | 72.0M | 63.5M | |
| End Period Cash Flow | 422.6M | 699.3M | 415.2M | 510.9M | 587.5M | 616.9M | |
| Change To Inventory | (1.4M) | (3.6M) | (11.7M) | (4.4M) | (4.0M) | (3.8M) | |
| Stock Based Compensation | 5.3M | 7.8M | 9.9M | 9.6M | 11.1M | 11.6M | |
| Change To Account Receivables | (32.5M) | (4.2M) | (48.0M) | (38.4M) | (34.6M) | (32.9M) | |
| Investments | (38.8M) | (117.1M) | (415.8M) | (13.3M) | (12.0M) | (12.6M) | |
| Net Borrowings | (79.3M) | 209.4M | (5.2M) | (5.9M) | (5.3M) | (5.0M) | |
| Total Cashflows From Investing Activities | (39.1M) | (86.6M) | (155.1M) | (243.9M) | (219.5M) | (230.4M) | |
| Change To Operating Activities | (4.8M) | (30.6M) | (32.1M) | (55.9M) | (50.3M) | (47.8M) | |
| Change To Netincome | (31.2M) | 24.1M | 19.3M | (158.6M) | (142.7M) | (135.6M) | |
| Issuance Of Capital Stock | 250.0M | 403.1M | 355K | 219K | 251.9K | 239.3K |
Pair Trading with Evotec SE
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Evotec SE position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Evotec SE will appreciate offsetting losses from the drop in the long position's value.Moving together with Evotec Stock
Moving against Evotec Stock
| 0.91 | PFE | Pfizer Inc Fiscal Year End 4th of February 2025 | PairCorr |
| 0.88 | LLY | Eli Lilly | PairCorr |
| 0.88 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.72 | UPC | Universe Pharmaceuticals | PairCorr |
| 0.63 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
The ability to find closely correlated positions to Evotec SE could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Evotec SE when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Evotec SE - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Evotec SE ADR to buy it.
The correlation of Evotec SE is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Evotec SE moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Evotec SE ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Evotec SE can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evotec SE ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evotec SE. If investors know Evotec will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evotec SE listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.50) | Revenue Per Share | Quarterly Revenue Growth (0.06) | Return On Assets | Return On Equity |
The market value of Evotec SE ADR is measured differently than its book value, which is the value of Evotec that is recorded on the company's balance sheet. Investors also form their own opinion of Evotec SE's value that differs from its market value or its book value, called intrinsic value, which is Evotec SE's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evotec SE's market value can be influenced by many factors that don't directly affect Evotec SE's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evotec SE's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evotec SE is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evotec SE's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.